Evotec (EVO) Q3 2025 Earnings Call Transcript

Evotec reported YTD group revenue of EUR 535.1m (-7%), driven by D&PD weakness (EUR 391.9m, -12%) while Just‑Evotec Biologics grew to EUR 143.2m (+11%); adjusted group EBITDA was negative EUR 16.9m and YTD free cash flow improved 14%. Management announced a transformational Sandoz transaction with >$650m total upside including ~$350m initial consideration, plus a pipeline milestone potential >EUR 16bn (EUR ~500m expected cumulated returns through 2028), and confirmed 2025 guidance of EUR 760–800m revenue and EUR 30–50m adjusted EBITDA. Near‑term risks remain from the soft early discovery market, but cost‑out targets (EUR 60m in 2025, plus EUR 50m further initiatives) and a pivot to licensing/royalty, plus >$200m of AI/platform order value, improve medium‑term margin and cash visibility.

Analysis

Management’s pivot from owning capacity to monetizing technology creates a classic margin re‑shaping trade: lower capital intensity and higher gross margins per incremental revenue, but materially more timing risk because cash flows will shift from steady manufacturing fees to lumpy license, development and royalty streams. Modelers should stop treating revenue growth and free cash flow as tightly correlated over the next 12–36 months; instead, forecast lower recurring revenue growth volatility but higher variance in quarterly EBITDA depending on milestone timing and tech‑transfer success.

The strategic move also has immediate second‑order effects across the value chain. Competing CDMOs that built scale by deploying plant capacity now face a two‑front pressure: pricing and mix compression as customers are offered licensing/tech transfer alternatives, and potential margin capture flowing to suppliers of proprietary consumables (cell lines/media) if Evotec commercializes those assets. Expect a wave of deal activity — either partnerships to buy into continuous‑manufacturing IP or M&A among capacity‑heavy CDMOs — as acquirers try to rebalance exposure to capital intensity versus IP royalties.

Key risks and timing buckets are clear: near term (days–months) hinge on regulatory/transaction close mechanics and near‑term milestone recognitions; medium term (6–18 months) depends on successful tech transfers and Sandoz (and similar partners’) biosimilar launch economics; long term (2–4 years) depends on adoption curve for NAMs/AI platforms to expand addressable spend per program. Tail risks that would reverse the thesis include failed tech transfers, a prolonged trough in biotech VC activity that suppresses discovery outsourcing for multiple years, or biosimilar pricing dynamics that materially compress projected royalty pools.

Key Decisions for Investors

• Long EVO equity (size: 1–2% NAV). Entry: add on confirmed transaction close or a >10% post‑close retracement; horizon 12–24 months. Thesis: re‑rating as revenue mix shifts to higher‑margin licenses/royalties and FCF improves. Risk management: 15–20% stop or hedge with puts if newsflow on milestones disappoints.
• Buy a capped upside option structure on EVO to express convexity (e.g., 12–18 month call spread). Use this to limit premium outlay while capturing re‑rating from margin expansion and milestone recognition; target asymmetric payoff ~3x+ if two or more pipeline milestones are achieved. Drawback: time decay and binary milestone calendar risk.
• Relative value pair: long EVO / short Charles River Labs (CRL) 1:1 notional, 6–24 month horizon. Rationale: EVO benefits disproportionately from an IP/licensing pivot while CRL is exposed to legacy capacity overhang and pricing pressure. Hedge risk: CRL may outperform if manufacturing demand reaccelerates or if consolidation bid lifts both stocks.
• Event hedge: if holding EVO into near‑term regulatory/transaction milestones, buy 4–6 month protective puts (~5–8% notional) to cap downside from deal approval delays or a lumpy milestone miss. Cost is insurance against binary headline risk; acceptable burn if it prevents a material NAV haircut.